TriangleCapecitabine Oral Product (NCT04339036)
Capecitabine Oral Product trial for Neuroendocrine Tumor Grade 2 (NCT04339036). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with well-differentiated grade 2 or 3 neuroendocrine tumors and unresectable, liver-dominant metastases. Tumors must occupy no more than half the liver.
The idea: combine oral capecitabine and temozolomide, which disrupt DNA production or copying, with Y90 radioembolization. Radioactive microspheres deliver radiation through arteries to liver tumors. Planning angiography checks suitability. Radioembolization starts during cycle two if chemotherapy is tolerated; another treatment may follow. Researchers measure time without liver progression.
This phase 2 study plans 70 patients. Michael Soulen leads Penn’s recruiting Philadelphia site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.